Related Experiment Video
Updated: Jun 30, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Antitumoral and antiangiogenic activity of Synadenium umbellatum Pax
Iara Antonia L Nogueira1, Aryane B B Leão, Marcelo de S Vieira
1Laboratório de Farmacologia e Toxicologia Celular, Faculdade de Farmácia, Universidade Federal de Goiás, UFG, Goiânia, GO, Brazil.
Aim Of The Study:
Synadenium umbellatum Pax (SU), a plant used in the Midwestern region of Brazil, was tested for its antitumor and antiangiogenic activities in vitro, using K-562 and Ehrlich ascites tumor (EAT) cells, and in vivo, using the EAT-bearing model.
Materials And Methods:
The viability of tumor cells was evaluated by MTT and trypan blue exclusion assays, after incubation with the ethanolic extract of SU (EESU) (0.15-20mg/mL) or equivalent concentrations of its partitioned fractions (chloroformic, hexanic, and methanolic). In vivo studies were performed in EAT-bearing mice treated intraperitoneally with 5, 10, and 25mg/kg of the EESU or equivalent doses of the fractions for 10 days. The methotrexate (1.5mg/kg), for 10 days, was used as control.
Results:
SU and fractions, except the methanolic, decreased the viability of the cells in a concentration-dependent manner. In vivo results showed a significant dose-dependent antitumoral efficacy of SU against EAT growth. The best results in prolonging life span were produced by 25mg/kg of EESU. In these animals, the levels of vascular endothelial growth factor were markedly decreased after the treatment.
Conclusions:
The data presented herein could open interesting perspectives for further research of SU as a candidate anticancer agent.
